We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Affymetrix and Tessare Develop Pathogen-Detection Kit

By Biotechdaily staff writers
Posted on 12 Feb 2007
Affymetrix Inc. (Santa Clara, CA, USA) announced that it has granted Tessare, Inc. (Colorado Springs, CO, USA) non-exclusive access to its microarray technology to develop and market epidemiological tests for public health and biodefense surveillance.

As part of the Powered by Affymetrix program, the TessArray kits will detect and identify hundreds of strains of natural and emergent viral and bacterial pathogens, as well as biothreat agents. The resulting information will enable scientists to understand and respond to pandemic infectious disease threats.

The TessArray kits are based on multiplexed genotypic signatures present on the Affymetrix CustomSeq Resequencing Arrays. These arrays have been designed and fabricated to detect a set of upper respiratory pathogen-specific target sequences provided by the U.S. Naval Research Laboratory. Public health officials can use the resulting information to identify the most likely agent strain(s) associated with disease outbreaks.

Tessare president and co-founder Klaus Schafer, M.D., M.P.H., said, Investigators at collection sites can determine whether detected pathogen strains warrant elevated epidemic or pandemic concerns. The TessArray kits enable a level of strain and sub-strain discrimination not possible with other array-based methodologies, as well as the ability to detect and characterize novel nucleotide changes in the pathogen genome sequence at the same time.

With the recent emergence of new infectious diseases such as avian influenza, it is important for global health organizations to have access to comprehensive epidemiological surveillance research tools, said Robert Lipshutz, Ph.D., senior vice president, corporate development and emerging markets at Affymetrix. We are pleased to have Tessare join our Powered by Affymetrix program and we anticipate that the availability of these types of microarray-based testing kits and services will allow epidemiologists to better monitor the spread of pathogens and detect mutations that may alter their potential to cause a pandemic.






Related Links:
Affymetrix
Tessare

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Slide Scanner System
NanoZoomer S540MD
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
12 Feb 2007  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
12 Feb 2007  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
12 Feb 2007  |   BioResearch